Search
Galmed Pharmaceuticals Ltd
GLMDAdd to Watchlist
0.570USD
-0.079-12.34%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
3.13MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-12.34%
5 Days
-0.54%
1 Month
-21.87%
6 Months
-30.68%
Year to Date
-24.00%
1 Year
-68.75%
Key Figures
0.599Open
0.600High
108.60KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.98%Turnover Ratio
0.648Prev. Close
0.550Low
38.32KTurnover
LossP/E Static
0.16P/B
0.00%Div Yield TTM
-55.53%ROA
2.34052wk High
0.98Volume Ratio
-7.52MNet Profit
5.48MShares
-2.3912EPS TTM
0.68Beta
-64.21%ROE
0.41152wk Low
7.66%Amplitude
--Gross Margin
3.13MMarket Cap
-1.84Reward/Risk
6.13%Risk Rate
TradingKey Stock Score of Galmed Pharmaceuticals Ltd
Currency: USD Updated: 2026-07-02Key Insights
Galmed Pharmaceuticals Ltd's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 190 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 0.00.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Galmed Pharmaceuticals Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Galmed Pharmaceuticals Ltd Highlights
StrengthsRisks
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -0.24, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 224.38K shares, increasing 25.09% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.75.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
0.000
Target Price
0.00%
Upside Space
Galmed Pharmaceuticals Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Galmed Pharmaceuticals Ltd Info
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Ticker SymbolGLMD
CompanyGalmed Pharmaceuticals Ltd
CEOBaharaff (Allen)
Websitehttps://www.galmedpharma.com
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Galmed Pharmaceuticals Ltd (GLMD)?
The current price of Galmed Pharmaceuticals Ltd (GLMD) is 0.57.
What is the symbol of Galmed Pharmaceuticals Ltd?
The ticker symbol of Galmed Pharmaceuticals Ltd is GLMD.
What is the 52-week high of Galmed Pharmaceuticals Ltd?
The 52-week high of Galmed Pharmaceuticals Ltd is 2.34.
What is the 52-week low of Galmed Pharmaceuticals Ltd?
The 52-week low of Galmed Pharmaceuticals Ltd is 0.41.
What is the market capitalization of Galmed Pharmaceuticals Ltd?
The market capitalization of Galmed Pharmaceuticals Ltd is 3.13M.
What is the Earnings Per Share (EPS TTM) of Galmed Pharmaceuticals Ltd (GLMD)?
The Earnings Per Share (EPS TTM) of Galmed Pharmaceuticals Ltd (GLMD) is -2.39.